PARP1 and neoplasm: CRISPR/Cas9 directed genome editing of tumor-derived exosomes inhibit poly (ADP-ribose) polymerase-1 levels and enhance the sensitivity of the SKOV3 xenograft mouse model to cisplatin; exosomes loaded with PARP-1 sgR/Cas9 reduce the tumor size in vivo [258].